Myelodysplastic Syndromes (MDS)

Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial

Read more about Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial

Background: Lenalidomide Lenalidomide: Lenalidomide is a capsule that is taken by mouth.

Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms

Read more about Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms

Background: Hypomethylating agents (HMAs) are guideline-recommended treatment for higher-risk myelodysplastic syndromes mye

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial

Read more about Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial

Background: The preplanned interim analysis of the COMMANDS trial showed greater efficacy of luspatercept than epoetin alfa epoetin alfa: Epoetin alfa can help improv

Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation?

Read more about Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation?

For most patients with childhood myelodysplastic syndrome (cMDS), allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative option.

A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes

Read more about A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes

Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications

Read more about Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications

Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone

2024 EHA-ASCO Research Updates for MDS and AML

Thumbnail for video Watch Now

Topic(s)

Myelodysplastic Syndromes (MDS)

Acute Myeloid Leukemia (AML)

Presenter(s)

Abhay Singh, MD, MPH

In this webinar, Dr. Abhay Singh discusses the latest MDS and AML research presented at the 2024 EHA and ASCO meetings. This is an advanced educational presentation.

Pashna N. Munshi, MD

Institution

University of Pennsylvania

Primary Disease Area of Focus

Acute Myeloid Leukemia (AML)

Aplastic Anemia

Myelodysplastic Syndromes (MDS)

Myeloproliferative Neoplasms (MPN)

Read more about Pashna N. Munshi, MD

High-Risk MDS - 2024 Philadelphia Patient and Family Conference

Thumbnail for video Watch Now

Topic(s)

Myelodysplastic Syndromes (MDS)

Keith W Pratz, MD, explains High-Risk MDS, or Myelodysplastic Syndromes, in this recorded conference session. He details risk categories as well as treatments, plus anticipated research on the disease.

A Patient Story - from the 2024 Philadelphia Patient and Family Conference

Thumbnail for video Watch Now

Topic(s)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Aplastic Anemia

Living Well with Bone Marrow Failure

Myelodysplastic Syndromes (MDS)

Ellen Kalinosky describes her turbulent journey through multiple bone marrow failure diseases in this recording from the 2024 Philadelphia Patient and Family Conference.

Subscribe to Myelodysplastic Syndromes (MDS)

NFL Player Teams Up with AAMDSIF

Myelodysplastic Syndromes (MDS)

Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial

Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial

Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation?

A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes

Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications

2024 EHA-ASCO Research Updates for MDS and AML

Pashna N. Munshi, MD

High-Risk MDS - 2024 Philadelphia Patient and Family Conference

A Patient Story - from the 2024 Philadelphia Patient and Family Conference

Website Feedback